TNFSF10 and breast carcinoma: While these data are intriguing, breast cancer is a systemic disease; the role of combining TRAIL death receptor agonists would need to be carefully considered in instances where increased local control would be beneficial, such as in the setting of locally advanced or inflammatory breast cancer.